Page 116 - Read Online

Spencer et al. J Cancer Metastasis Treat 2022;8:2 https://dx.doi.org/10.20517/2394-4722.2021.174 Page 15 of 15

Oncologist 2016;21:1471-82. DOI PubMed PMC
72. Sowers R, Wenzel BD, Richardson C, et al. Impairment of methotrexate transport is common in osteosarcoma tumor samples.
Sarcoma 2011;2011:834170. DOI PubMed PMC
73. Winer A, Adams S, Mignatti P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol
Cancer Ther 2018;17:1147-55. DOI PubMed PMC
74. Fields GB. The Rebirth of matrix metalloproteinase inhibitors: moving beyond the dogma. Cells 2019;8:984. DOI PubMed PMC
75. BT1718 in patients with advanced solid tumours. Available from: https://ClinicalTrials.gov/show/NCT03486730 [Last accessed on 6
Dec 2021].
76. Bennett G, Rigby M, Lutz B, Park P, Keen N. Abstract B135: The mechanism of action of BT1718, a novel small-molecule drug
conjugate for the treatment of solid tumors expressing MT1-MMP. Mol Cancer Ther 2018;17:B135. DOI
77. Atkinson JM, Falconer RA, Edwards DR, et al. Development of a novel tumor-targeted vascular disrupting agent activated by
membrane-type matrix metalloproteinases. Cancer Res 2010;70:6902-12. DOI PubMed PMC
78. Gill JH, Loadman PM, Shnyder SD, et al. Tumor-targeted prodrug ICT2588 demonstrates therapeutic activity against solid tumors and
reduced potential for cardiovascular toxicity. Mol Pharm 2014;11:1294-300. DOI PubMed
79. Li S, Sun Z, Meng X, et al. Targeted methotrexate prodrug conjugated with heptamethine cyanine dye improving chemotherapy and
monitoring itself activating by dual-modal imaging. Front Mater 2018;5:35. DOI